

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



丽珠医药
LIVZON

麗珠醫藥集團股份有限公司

LIVZON PHARMACEUTICAL GROUP INC.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1513)

CANCELLATION OF SHARE OPTIONS UNDER THE 2018 SHARE OPTIONS INCENTIVE SCHEME

Reference is made to the announcements of 麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 17 July 2018, 18 July 2018, 29 July 2018, 17 August 2018, 31 August 2018, 5 September 2018, 11 September 2018, 8 October 2018, 28 August 2019, 18 September 2019, 16 October 2019, 20 November 2019, 23 October 2020, 2 November 2020, 9 November 2020, 10 November 2021 and 17 February 2023, and the circular of the Company dated 18 August 2018 (the “**Circular**”) in relation to, among others, the proposed adoption of the 2018 Share Options Incentive Scheme (Revised Draft) (the “**Incentive Scheme**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

As set out in the announcement of the Company dated 17 February 2023, on 17 February 2023, the Company intended to cancel a total of 4,859,734 Share Options which were not yet exercised under the exercise period of the First Grant and no longer satisfying the conditions for incentive of the First Grant, and a total of 45,278 Share Options which were not yet exercised under the exercise period of the Reserved Grant.

On 7 March 2023, after verification and confirmation by Shenzhen Branch of China Securities Depository and Clearing Co., Ltd., the above-mentioned cancellation of Share Options has been completed.

By order of the Board
麗珠醫藥集團股份有限公司
Livzon Pharmaceutical Group Inc. *
Yang Liang
Company Secretary

Zhuhai, China

7 March 2023

As at the date of this announcement, the Executive Directors of the Company are Mr. Tang Yanggang (President) and Mr. Xu Guoxiang (Vice Chairman and Vice President); the Non-Executive Directors of the Company are Mr. Zhu Baoguo (Chairman), Mr. Tao Desheng (Vice Chairman), Mr. Qiu Qingfeng and Mr. Yu Xiong; and the Independent Non-Executive Directors of the Company are Mr. Bai Hua, Mr. Tian Qiusheng, Mr. Wong Kam Wa, Mr. Luo Huiyuan and Ms. Cui Lijie.

** For identification purpose only*